Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

istrative expenses is primarily due to cost savings related to recent restructurings.

The Company's balance sheet on September 30, 2008 reflected total assets of $207.7 million, including cash and investments of $118.2 million compared with balances at December 31, 2007 of $276.7 million and $179.4 million, respectively. The Company expects to end 2008 with approximately $100 million in cash and investments.

"We are pleased with the progress of our GnRH program, especially the recent positive results of our 603 study where once a day elagolix showed profound efficacy with minimal impact on bone mineral density. We are also nearing completion of the final preclinical studies of urocortin 2 to allow for long-term Phase II clinical studies and our scientists have just recently identified a clinical candidate from our VMAT2 development program for movement disorders," said Kevin Gorman, Chief Executive Officer and President of Neurocrine Biosciences. "While we are making great strides in advancing our pipeline, we continue to prioritize expenditures and diligently manage our cash burn."

R & D Pipeline Update

Neurocrine's clinical development group and corporate partners have five programs in clinical development. Neurocrine scientists continue to supply Neurocrine's pipeline to meet the Company-wide goal of bringing one new compound into development each year.

Elagolix for Endometriosis

The Company recently announced the positive safety and efficacy results from the completed 6-month treatment phase of its Phase IIb clinical trial (PETAL Study) using its proprietary, orally-active nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix.

The primary endpoint, percent change from baseline in mean bone mineral density (BMD) demonstrated elagolix did not induce significant bone loss over the six month treatment period. Additionally, elagolix also met the secondary endpoints of improvement in endometrios
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)...   , ... zu KLOX    Mariano ... Officer bestellt    KLOX ist bestens ... zugelassenen Behandlungssystems zur Wundheilung zu beginnen    , ... sehr erfreut, die folgenden personellen Veränderungen anzukündigen: ...
(Date:11/21/2014)... (PRWEB) November 20, 2014 Offering a ... Sartorius Entris Balance promotion . The Sartorius Entris ... a durable, high accuracy, and easy-to-maintain balance entry level ... Germany. It was designed to help customer’s bridge the ... a balance that is very durable. Sartorius is the ...
(Date:11/21/2014)... 2014 The November 2014 issue of ... open access journal featuring the following articles:, ... preserve photoresponsiveness in the retina , DNA ... hybridization using chromogenic substrates in zebrafish , ... protein electrophoresis , Nuclear LC3-positive puncta in ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... Industry” is a professional and in-depth research report ... information, including its definition, classification, application, and industry ... research covers the international market analysis, including China’s ... covering macroeconomic environment & economic situation analysis. The ...
Breaking Biology Technology:KLOX Technologies meldet Neubesetzung von Führungspositionen 2KLOX Technologies meldet Neubesetzung von Führungspositionen 3KLOX Technologies meldet Neubesetzung von Führungspositionen 4KLOX Technologies meldet Neubesetzung von Führungspositionen 5Pipette.com Announces an Extension on the Sartorius Entris Balance Promotion to the End of 2014 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 2International Transformer Industry - Analysis on Applications, Development & Forecasts Now Available at ReportsnReports.com 3
... Del., July 13 ParagonRx, a Delaware-based company which specializes in ... website - www.paragonrx.com - that includes a ... in complying with new FDA requirements to ensure the medical benefits ... , "REMS, or Risk Evaluation and ...
... , NEWARK, N.J., July 13 ... technology-based Life Science company announced today that at ATS Labs using ... Ygiene(TM) formula produced a 100% Total Kill of ... required AOAC Sporicidal Test utilizing spore impregnated then knotted suture loops ...
... , HOLMDEL, N.J., July 13 ... quality and compliance management software, today announced that ... products, has deployed Sparta,s TrackWise ((R)) Enterprise Quality ... across its manufacturing operations in Canada and the United ...
Cached Biology Technology:ParagonRx Creates New Website Featuring REMS Help Center for Pharma 2BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms 2BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms 3BioNeutral's Ygiene(TM) Hospital Grade Achieves World Class Independent Test Results in Killing Life Threatening Spores/Organisms 4Sparta Systems' TrackWise(R) Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 2Sparta Systems' TrackWise(R) Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 3Sparta Systems' TrackWise(R) Solution Delivers Workforce Training and Learning Initiatives for Cangene Corporation 4
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/3/2014)... , Nov. 3, 2014 Research and ... "Cell Therapy - Technologies, Markets and Companies" to ... cell therapy technologies and methods, which have already started to ... stem cell transplantation is replacing the old fashioned bone marrow ... Cell therapy is bound to become a part of medical ...
(Date:11/3/2014)... and preterm birth are linked to increased risk for ... the American College of Rheumatology (ACR) journal, Arthritis ... and pre-term babies were not at greater risk of ... According to the ACR, 27 million Americans over the ... of OA range from mild to severe and include ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... fuel sources are lighting a fire under research to turn ... Bill 20, signed this week by Gov. Rick Perry, compliments ... used. The new law requires more renewable energy to be ... consumer energy needs and agriculture industry trends with the legislation ...
... some day be defeated by a single treatment, according ... University of Georgia's College of Veterinary Medicine. , Their ... and Marburg and includes investigators from Vanderbilt University Medical ... The study is being funded by a grant from ...
... Berkeley, has found that damage to a cell's DNA sets ... of a marker recognized by the body's immune system. , ... advanced online issue of Nature, shed light on a long-standing ... are able to attack tumors - can differentiate cells that ...
Cached Biology News:Researchers find ways to turn manure into power 2Researchers find ways to turn manure into power 3Researcher at UGA College of Veterinary Medicine identifies new way of combating viral diseases 2New study finds how cells with damaged DNA alert the immune system 2New study finds how cells with damaged DNA alert the immune system 3
... spatulas have been designed to save time ... those interested in eliminating the recycling and ... is individually packaged, RNase/DNase free, non-pyrogenic and ... new product number, created to easily match ...
... mechanical harvesting of cells • Blade design ... with the growth surface • Designed for ... Individually wrapped • Sterilized by gamma radiation ... is a new product number, created to ...
... kit for a single fragment based screening project: , ... , 96 shape-diverse mixtures of 4 (5 ... files for structure refinement , Individual compounds ... are at ca. 50 mM. Supplied in 5 96-well trays. ...
... interferons are cytopathic effect inhibition assays, also ... The neutralization assay measures the antibody's ability ... cytokine. Sample types include; tissue culture supernatents; ... assays, one unit is defined as the ...
Biology Products: